Works matching IS 00079235 AND DT 2024 AND VI 74 AND IP 5
Results: 6
Osimertinib prolongs progression‐free lung cancer survival after chemotherapy.
- Published in:
- CA: A Cancer Journal for Clinicians, 2024, v. 74, n. 5, p. 402, doi. 10.3322/caac.21862
- By:
- Publication type:
- Article
Cancer disparities for LGBTQ+ patients identified more fully.
- Published in:
- CA: A Cancer Journal for Clinicians, 2024, v. 74, n. 5, p. 399, doi. 10.3322/caac.21861
- By:
- Publication type:
- Article
Proportion and number of cancer cases and deaths attributable to potentially modifiable risk factors in the United States, 2019.
- Published in:
- CA: A Cancer Journal for Clinicians, 2024, v. 74, n. 5, p. 405, doi. 10.3322/caac.21858
- By:
- Publication type:
- Article
Cancer misinformation on social media.
- Published in:
- CA: A Cancer Journal for Clinicians, 2024, v. 74, n. 5, p. 453, doi. 10.3322/caac.21857
- By:
- Publication type:
- Article
The evolving landscape of tissue‐agnostic therapies in precision oncology.
- Published in:
- CA: A Cancer Journal for Clinicians, 2024, v. 74, n. 5, p. 433, doi. 10.3322/caac.21844
- By:
- Publication type:
- Article
Issue Information.
- Published in:
- CA: A Cancer Journal for Clinicians, 2024, v. 74, n. 5, p. 397, doi. 10.3322/caac.21798
- Publication type:
- Article